References

1 Bennet SJ, Huster GA, Baker SL, Milgrom ALB, Kirchgassner Birt J, et al. Characterization of the precipiatants of hospitalization for heart failure decompensation. Am J Crit Care 7 (1998) 168-174.

2 Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 80 (1998) 437-441.

3 Tsuyuki RT, McKelvie RS, Arnold JM, Avezum A. Jr, Barretto AC, Carvalho AC, et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 161 (2001) 2337-2342.

4 Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82 (1990) 1724-1729.

5 Colin Ramirez E, Castillo Martinez L, Orea Tejeda A, Rebollar Gonzalez V, Narvaez David R, Asensio Lafuente E. Effects of a nutritional intervention on body composition, clinical status, and quality of life in patients with heart failure. Nutrition 20 (2004) 890-895.

6 Meadows R, Johnson ED. Clinical inquiries. Does a low salt diet reduce morbidity and mortality in congestive heart failure? J Fam Pract 51 (2002) 615.

7 American Heart Association website. http://www.americanheart.org/presenter.jhtml?identifier=4708. Accessed November 25, 2008.

8 Estes EH. Jr, Sieker HO, Mclntosh HD, Kelser GA. Reversible cardio-pulmonary syndrome with extreme obesity. Circulation 16 (1957) 179-187.

9 Alpert MA, Terry BE, Mulekar M, Cohen MV, Massey CV, Fan TM, et al. Cardiac morphology and left ventricular function in normoten-sive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol 80 (1997) 736-740.

10 Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38 (2001) 789-795.

11 Davos CH, Doehner W, Rauchhaus M, Ciciora M, Francis DP, Coats AJ, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card. Fail 9 (2003) 29-35.

12 Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 165 (2005) 55-61.

13 Fonarow GC. The relationship between body mass index and mortality in patients hospitalized with acute decompensated heart failure. Am Heart J 154 (2007) e21.

14 Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, et al. Booody mass index and prognosis in patients with heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 116 (2007) 627-636.

15 Pischon T, Boeing H, Hoffman; et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 359 (2008) 2105-2120.

16 Ammar KA, Redfield MM, Mahoney DW, Johnson M, Jacobsen SJ, Rodeheffer RJ. Central obesity: association with left ventricular dysfunction and mortality in the community. Am Heart J 156 (2008) 975-981.

17 Sagar UN, Ahmed MM, Adams S, Whellan DJ. Does body mass index really matter in the management of heart failure: a review of the literature. Cardiol Rev 16 (2008) 124-128.

18 Mohamed-Ali v; Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 277 (1999) E971-E975.

19 Hernandez AF, Whellan DJ, Stroud S, Sun JL, O'Connor CM, Jollis JG. Outcomes in heart failure patients after major noncardiac surgery. J Am Coll Cardiol 44 (2004) 1446-1453.

20 Flum DR, Dellinger EP. Impact of gastric bypass operation on survival: a population-based analysis. J Am Coll Surg 199 (2004) 543-551.

21 Ikonomidis I, Mazarakis A, Papadopoulis C, Patsouras N, Kalfarentzos F, Lekakis J, et al. Weight loss after bariatric surgery improves aortic elastic properties and left ventricular function in individuals with morbid obesity: a 3-year follow-up study. J Hypertens 25 (2007) 439-447.

22 Ristow B, Rabkin J, Haeusslein E. Improvement in dilated cardiomyopathy after bariatric surgery. J Card Fail 14 (2008) 198-202.

23 McClosky CA, Ramani GV, Mathier MA, Schauer PR, Eid GM, Mattar SG, et al. Bariatric surgery improves cardiac function in morbidly obese patients with severe cardiomyopathy. Surg Obes Relat Dis 3 (2007) 503-507.

24 Whellan DJ, Gaulden L, Gattis WA, Granger B, Russell SD, Blazing MA, et al. The benefit of implementing a heart failure disease management program. Arch Intern Med 161 (2001) 2223-2228.

25 Gibbs CR, Jackson G, Lip GY. ABC of heart failure. Non-drug management. BMJ 320 (2000) 366-369.

26 English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 102 (2000) 1906-1911.

27 Ershow AG, Costello RB. Dietary guidance in heart failure: a perspective on needs for prevention and management. Heart Fail Rev 11 (2006) 7-12.

28 Witte KK, Clark AL. Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives. Heart Fail Rev 11 (2006) 65-74.

29 Gorelik O, Almoznino-Sarafian D, Feder I, Wachsman O, Alon I, Litvinjuk V, et al. Dietary intake of various nutrients in older patients with congestive heart failure. Cardiology 99 (2003) 177-181.

30 Ackman ML, Campbell JB, Buzak KA, Tsuyuki RT, Montague TJ, Teo KK. Use of nonprescription medications by patients with congestive heart failure. Ann Pharmacother 33 (1999) 674-679.

31 Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M, on behalf of the Survival and Prognosis; ; Investigation of Crataegus Extract WS(R) 1442 in CHF (SPICE) trial study group. The efficacy and safety of Crataegus extract WS(R) 1442 in patients with heart failure: The SPICE trial. Eur J Heart Fail (2008 Nov 17).

32 D'Arcy PF. Adverse reactions and interactions with herbal medicines. Part 2-Drug interactions. Adverse Drug React Toxicol Rev 12 (1993) 147-162.

33 Javaheri S, Parker TJ, Liming JD, Corbett WS, Nishiyama H, Wexler L, et al. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalence, consequences, and presentations. Circulation 97 (1998) 2154-2159.

34 Sin DD, Fitzgerald F, Parker JD, Newton G, Floras JS, Bradley TD. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 160 (1999) 1101-1106.

35 Tremel F, Pepin JL, Veale D, Wuyam B, Siche JP, Mallion JM, et al. High prevalence and persistence of sleep apnoea in patients referred for acute left ventricular failure and medically treated over 2 months. Eur Heart J 20 (1999) 1201-1209.

36 Pepperell JC, Maskell NA, Jones DR, Langford-Wiley BA, Crosthwaite N, Stradling JR, et al. A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. Am J Respir Crit Care Med 168 (2003) 1109-1114.

37 Kaneko Y, Floras JS, Usui K, Plante J, Tkacova R, Kubo T, Ando S, Bradley TD. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 348 (2003) 1233-1241.

38 Blankfield RP, Ahmed M, Zyzanski SJ. Effect of nasal continuous positive airway pressure on edema in patients with obstructive sleep apnea. Sleep Med 5 (2004) 589-592.

39 Usui K, Bradley TD, Spaak J, Ryan CM, Kubo T, Kaneko Y, Floras JS. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure. J Am Coll Cardiol 45 (2005) 2008-2011.

40 Ryan CM, Usui K, Floras JS, Bradley TD. Effect of continuous positive airway pressure on ventricular ectopy in heart failure patients with obstructive sleep apnoea. Thorax 60 (2005) 781-785.

41 Bradley TD, Logan AG, Kimoff RJ, Series F, Morrison D, Ferguson K, et al. CANPAP Investigators. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 353 (2005) 2025-2033.

42 Sullivan M, Levy WC, Russo JE, Spertus JA. Depression and health status in patients with advanced heart failure: a prospective study in tertiary care. J Card Fail 10 (2004) 390-396.

43 Friedmann E, Thomas SA, Liu F, Morton PG, Chapa D, Gottlieb SS. Sudden Cardiac Death in Heart Failure Trial Investigators. Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality. Am Heart J 152 (2006). 940.e1-e8.

44 Westlake C, Dracup K, Fonarow G, Hamilton M. Depression in patients with heart failure. J Card Fail 11 (2005) 30-35.

45 Rumsfeld JS, Jones PG, Whooley MA, Sullivan MD, Pitt B, Weintraub WS, Spertus JA. Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. Am Heart J 150 (2005) 961-967.

46 Havranek EP, Spertus JA, Masoudi FA, Jones PG, Rumsfeld JS. Predictors of the onset of depressive symptoms in patients with heart failure. J Am Coll Cardiol 44 (2004) 2333-2338.

47 O'Connor CM, Jiang W, Kuchibhatla M, Mehta RH, Clary GL, Cuffe MS, et al. Antidepressant use, depression, and survival in patients with heart failure. Arch Int Med 168 (2008) 2232-2237.

48 Jiang W, Kuchibhatla M, Cuffe MS, Christopher EJ, Alexander JD, Clary GL, et al. Prognostic value of anxiety and depression in patients with chronic heart failure. Circulation 110 (2004) 3452-3456.

49 Glueck BC, Stroebel CF. Biofeedback and meditation in the treatment of psychiatric illnesses. Curr Psychiatr Ther 15 (1975) 109-116.

50 Middlekauff HR, Hui K, Yu JL, Hamilton MA, Fonarow GC, Moriguchi J, et al. Acupuncture inhibits sympathetic activation during mental stress in advanced heart failure patients. J Card Fail 8 (2002) 399-406.

51 Schwarz ER, Rastogi S, Kapur V, Sulemanjee N, Rodriguez JJ. Erectile dysfunction in heart failure patients. J Am Coll Cardiol 48 (2006) 1111-1119.

52 Hirata K, Adji A, Vlachopoulos C, O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 96 (2005) 1436-1440.

53 Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115 (2007) 59-66.

54 Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 106 (2002) 1097-1103.

55 Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol 37 (2001) 1677-1682.

56 Aguilar D, Skali H, Moye LA, Lewis EF, Gaziano JM, Rutherford JD, et al. Alcohol consumption and prognosis in patients with left ventri cular systolic dysfunction after a myocardial infarction. J Am Coll Cardiol 43 (2004) 2015-2021.

57 Salisbury AC, House JA, Conard MW, Krumholz HM, Spertus JA. Low-to-moderate alcohol intake and health status in heart failure patients. J Card Fail 11 (2005) 323-328.

58 Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116 (2007) 1736-1754.

59 Bleumink GS, Feenstra J, Sturkenboom MC, Strieker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 63 (2003) 525-534.

60 Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 92 (2006) 1610-1615.

61 Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 330 (2005) 1370.

62 Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363 (2004) 1751-1756.

63 O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301 (2009) 1439-1450.

64 Flynn KE, Pina IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301 (2009) 1451-1459.

65 Keteyian SJ, Houston-Miller N, Leifer ES, O'Connor CM, Whellan DM, Cooper LS, et al. A dose-response analysis of patients with heart failure enrolled in a controlled trial investigating outcomes of exercise training (HF-ACTION). American College of Cardiology (March 29, 2009).

66 Coats AJ, Adamopoulos S, Meyer TE, Conway J, Sleight P. Effects of physical training in chronic heart failure. Lancet 335 (1990) 63-66.

67 Coats AJ, Adamopoulos S, Radaelli A, McCance A, Meyer TE, Bernard! L, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 85 (1992) 2119-2131.

68 Belardinelli R, Georgiou D, Scocco V, Barstow TJ, Purcaro A. Low intensity exercise training in patients with chronic heart failure. J Am Coll Cardiol 26 (1995) 975-982.

69 Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 99 (1999) 1173-1182.

70 Hambrecht R, Niebauer J, Fiehn E, Kalberer B, Offner B, Hauer K, et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J Am Coll Cardiol 25 (1995) 1239-1249.

71 Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial. JAMA 283 (2000) 3095-3101.

72 Keteyian SJ, Levine AB, Brawner CA, Kataoka T, Rogers FJ, Schairer JR, et al. Exercise training in patients with heart failure. A randomized, controlled trial. Ann Intern Med 124 (1996) 1051-1057.

73 Keteyian SJ, Brawner CA, Schairer JR, Levine TB, Levine AB, Rogers FJ, et al. Effects of exercise training on chronotropic incompetence in patients with heart failure. Am Heart J 138 (1999) 233-240.

74 Kiilavuori K, Toivonen L, Naveri H, Leinonen H. Reversal of autonomic derangements by physical training in chronic heart failure as sessed by heart rate variability. Eur Heart J 16 (1995) 490-495.

75 Kiilavuori K, Sovijarvi A, Naveri H, Ikonen T, Leinonen H. Effect of physical training on exercise capacity and gas exchange in patients with chronic heart failure. Chest 110 (1996) 985-991.

76 Koch M, Douard H, Broustet JR. The benefit of graded physical exercise in chronic heart failure. Chest 101 (5 Suppl) (1992) 231S-235S.

77 Wielenga RP, Huisveld IA, Bol E, Dunselman PH, Erdman RA, Baselier MR, et al. Exercise training in elderly patients with chronic heart failure. Coron Artery Dis 9 (1998) 765-770.

78 Willenheimer R, Erhardt L, Cline C, Rydberg E, Israelsson B. Exercise training in heart failure improves quality of life and exercise capacity. Eur Heart J 19 (1998) 774-781.

79 Kiilavuori K, Naveri H, Leinonen H, Harkonen M. The effect of physical training on hormonal status and exertional hormonal response in patients with chronic congestive heart failure. Eur Heart J 20 (1999) 456-464.

80 Adamopoulos S, Piepoli M, McCance A, Bernard! L, Rocadaelli A, Ormerod O, et al. Comparison of different methods for assessing sympathovagal balance in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 70 (1992) 1576-1582.

81 Adamopoulos S, Ponikowski P, Cerquetani E, Piepoli M, Rosano G, Sleight P, et al. Orcadian pattern of heart rate variability in chronic heart failure patients. Effects of physical training. Eur Heart J 16 (1995) 1380-1386.

82 Radaelli A, Coats AJ, Leuzzi S, Piepoli M, Meyer TE, Calciati A, et al. Physical training enhances sympathetic and parasympathetic control of heart rate and peripheral vessels in chronic heart failure. Clin Sci (Lond) 91 (1996) 92-94.

83 Katz SD, Yuen J, Bijou R, LeJemtel TH. Training improves endo-thelium-dependent vasodilation in resistance vessels of patients with heart failure. J Appl Physiol 82 (1997) 1488-1492.

84 Tyni-Lenne R, Gordon A, Jansson E, Bermann G, Sylven C. Skeletal muscle endurance training improves peripheral oxidative capacity, exercise tolerance, and health-related quality of life in women with chronic congestive heart failure secondary to either ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 80 (1997) 1025-1029.

85 Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 342 (2000) 454-460.

86 Ehsani AA, Heath GW, Hagberg JM, Sobel BE, Holloszy JO. Effects of 12 months of intense exercise training on ischemic ST-segment depression in patients with coronary artery disease. Circulation 64 (1981) 1116-1124.

87 Schuler G, Hambrecht R, Schlierf G, Grunze M, Methfessel S, Hauer K, et al. Myocardial perfusion and regression of coronary artery disease in patients on a regimen of intensive physical exercise and low fat diet. J Am Coll Cardiol 19 (1992) 34-42.

88 Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 86 (1992) 1-11.

89 Niebauer J, Hambrecht R, Marburger C, Hauer K, Velich T, von Hodenberg E, et al. Impact of intensive physical exercise and low-fat diet on collateral vessel formation in stable angina pectoris and angiographically confirmed coronary artery disease. Am J Cardiol 76 (1995) 771-775.

90 McKelvie RS, Teo KK, Roberts R, McCartney N, Humen D, Montague T, et al. Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J 144 (2002) 23-30.

91 Szlachcic J, Massie BM, Kramer BL, Topic N, Tubau J. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol 55 (1985) 1037-1042.

92 Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH. Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83 (1991) 778-786.

93 Stelken AM, Younis LT, Jennison SH, Miller DD, Miller LW, Shaw LJ, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol 27 (1996) 345-352.

94 Myers J. Effects of exercise training on abnormal ventilatory responses to exercise in patients with chronic heart failure. Congest Heart Fail 6 (2000) 243-249.

95 Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol 47 (1981) 33-39.

96 Higginbotham MB, Morris KG, Conn EH, Coleman RE, Cobb FR. Determinants of variable exercise performance among patients with severe left ventricular dysfunction. Am J Cardiol 51 (1983) 52-60.

97 Conn EH, Williams RS, Wallace AG. Exercise responses before and after physical conditioning in patients with severely depressed left ventricular function. Am J Cardiol 49 (1982) 296-300.

98 Wilson JR, Martin JL, Schwartz D, Ferraro N. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle. Circulation 69 (1984) 1079-1087.

99 Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Muscle blood flow is reduced with maintenance of arterial perfusion pressure. Circulation 80 (1989) 769-781.

100 Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (1987) 524-526.

101 Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84 (1987) 9265-9269.

102 Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 84 (1991) 1589-1596.

103 Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 93 (1996) 210-214.

104 Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 98 (1998) 2709-2715.

105 Wilson JR, Mancini DM, Dunkman WB. Exertional fatigue due to skeletal muscle dysfunction in patients with heart failure. Circulation 87 (1993) 470-475.

106 Wiener DH, Fink LI, Maris J, Jones RA, Chance B, Wilson JR. Abnormal skeletal muscle bioenergetics during exercise in patients with heart failure: role of reduced muscle blood flow. Circulation 73 (1986) 1127-1136.

107 Massie BM, Conway M, Rajagopalan B, Yonge R, Frostick S, Ledingham J, et al. Skeletal muscle metabolism during exercise under ischemic conditions in congestive heart failure. Evidence for abnormalities unrelated to blood flow. Circulation 78 (1988) 320-326.

108 Lipkin DP, Jones DA, Round JM, Poole-Wilson PA. Abnormalities of skeletal muscle in patients with chronic heart failure. Int J Cardiol 18 (1988) 187-195.

109 Mancini DM, Coyle E, Coggan A, Beltz J, Ferraro N, Montain S, et al. Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure. Circulation 80 (1989) 1338-1346.

110 Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation 81 (1990) 518-527.

111 Sullivan MJ, Higginbotham MB, Cobb FR. Increased exercise ventilation in patients with chronic heart failure: intact ventilatory control despite hemodynamic and pulmonary abnormalities. Circulation 77 (1988) 552-559.

112 Piepoli MF. Exercise training in heart failure. Curr Heart Fail Rep 3 (2006) 33-40.

113 Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 149 (2005) 391-401.

114 Abboud C, Lichtman MA. Structure of the marrow. In: (editors: Beuier ELM, Coller BS, Kipps TJ. ) Williams Hematology. (1995) McGraw Hill: New York NY, pp. 25-38.

115 Adams KF, Patterson JH, Pina I, Ghali JK, Mehra MR, Oren RM, et al. STAMINA-HFP (Study of anemia in a heart failure population) regis try: rationale, design and patient characteristics. J Card Failure 9 (Suppl) (2003) S73.

116 Wagoner LE, Butler J, Oren RM, Ghali JK, Pina I, Miller AB, et al. Anemia is common in patients with heart failure seen in specialty and community cardiology clinics: results from the STAMINA-HFP registry (Study of anemia in a heart failure population). J Am Coll Cardiol 43 (Suppl) (2004) 217A.

117 Iverson PO, Woldbaek PR, Tonnessen T, Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Amer J Physiol 282 (2002) R166-R172.

118 Chatterjee B, Nydegger UE, Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur J Heart Fail 2 (2000) 393-398.

119 Salahudeen AK, Oliver B, Bower JD, Roberts LJ. 2nd. Increase inplasmaesterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 60 (2001) 1525-1531.

120 Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? Am J Kidney Dis 28 (1996) 535-540.

121 Adams KF, Pina I, Pavlovic-Surjancev B, Wagoner LE, Dunlap SH, Schwartz TA, et al. Anemia is associated with reduced health status measures in patients with heart failure: results from the STAMINA-HFP (study of anemia in a heart failure population) registry. J Am Coll Cardiol 43 (Suppl) (2004) 217A.

122 Herzog CA, Guo H, Collins AJ. Hospitalization rates for chronic heart failure patients in the Medicare population: the impact of kidney disease and anemia. J Card Failure 8 (Suppl) (2002) S73.

123 Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39 (2002) 1780-1786.

124 Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962.

125 Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 41 (2003) 1933-1939.

126 Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, et al. Hemodilution is common in patients with advanced heart failure. Circulation 107 (2003) 226-229.

127 Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107 (2003) 294-299.

128 Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lusher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 (2009) 2436-2448.

129 Mann JF. Hypertension and cardiovascular effects-long-term safety and potential long-term benefits of r-HuEPO. Nephrol Dial Transplant 10 (Suppl 2) (1995) 80-84.

130 Tang WW, Stead RA, Goodkin DA. Effects of epoetin alfa on hemostasis in chronic renal failure. Am J Nephrol 18 (1998) 263-273.

131 Taylor JE, McLaren M, Henderson IS, Belch JJ, Stewart WK. Pro-thrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant 7 (1992) 235-239.

132 Wolf RF, Gilmore LS, Friese P, Downs T, Burstein SA, Dale GL. Erythropoietin potentiates thrombus development in a canine arteriovenous shunt model. Thromb Haemost 77 (1997) 1020-1024.

133 Macdougall 1C, Davies ME, Halett I, Cochlin DL, Hutton RD, Coles GA, et al. Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 1991;6:862-867.

134 Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 4 (1994) 1809-1813.

135 Muirhead N, Laupacis A, Wong C. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadi an Erythropoietin Study Group). Nephrol Dial Transplant 7 (1992) 811-816.